185 related articles for article (PubMed ID: 27140314)
61. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
62. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
Goldsmith KC; Lestini BJ; Gross M; Ip L; Bhumbla A; Zhang X; Zhao H; Liu X; Hogarty MD
Cell Death Differ; 2010 May; 17(5):872-82. PubMed ID: 19893570
[TBL] [Abstract][Full Text] [Related]
63. Mimicking the BH3 domain to kill cancer cells.
Ni Chonghaile T; Letai A
Oncogene; 2008 Dec; 27 Suppl 1(0 1):S149-57. PubMed ID: 19641500
[TBL] [Abstract][Full Text] [Related]
64. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
Chappell WH; Abrams SL; Franklin RA; LaHair MM; Montalto G; Cervello M; Martelli AM; Nicoletti F; Candido S; Libra M; Polesel J; Talamini R; Milella M; Tafuri A; Steelman LS; McCubrey JA
Cell Cycle; 2012 Dec; 11(23):4447-61. PubMed ID: 23159854
[TBL] [Abstract][Full Text] [Related]
65. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells.
Zeuner A; Pedini F; Francescangeli F; Signore M; Girelli G; Tafuri A; De Maria R
Blood; 2009 Feb; 113(7):1522-5. PubMed ID: 19060244
[TBL] [Abstract][Full Text] [Related]
66. HA14-1, but not the BH3 mimetic ABT-737, causes Ca2+ dysregulation in platelets and human cell lines.
Akl H; Vandecaetsbeek I; Monaco G; Kauskot A; Luyten T; Welkenhuyzen K; Hoylaerts M; De Smedt H; Parys JB; Bultynck G
Haematologica; 2013 Apr; 98(4):e49-51. PubMed ID: 23403318
[No Abstract] [Full Text] [Related]
67. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia.
Mizukawa B; Wei J; Shrestha M; Wunderlich M; Chou FS; Griesinger A; Harris CE; Kumar AR; Zheng Y; Williams DA; Mulloy JC
Blood; 2011 Nov; 118(19):5235-45. PubMed ID: 21940819
[TBL] [Abstract][Full Text] [Related]
68. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KC; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW
Cell Rep; 2013 Nov; 5(4):1047-59. PubMed ID: 24268771
[TBL] [Abstract][Full Text] [Related]
69. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.
Soderquist R; Bates DJ; Danilov AV; Eastman A
Leukemia; 2013 Nov; 27(11):2262-4. PubMed ID: 23640104
[No Abstract] [Full Text] [Related]
70. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
[TBL] [Abstract][Full Text] [Related]
71. Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Adams JM; Strasser A
Cell Death Differ; 2013 Jan; 20(1):57-63. PubMed ID: 22814621
[TBL] [Abstract][Full Text] [Related]
72. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
[TBL] [Abstract][Full Text] [Related]
73. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.
Cragg MS; Harris C; Strasser A; Scott CL
Nat Rev Cancer; 2009 May; 9(5):321-6. PubMed ID: 19343035
[TBL] [Abstract][Full Text] [Related]
74. BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JM; Nicholson RI; Print CG; Clark SJ; Musgrove EA
Mol Cancer Ther; 2013 Sep; 12(9):1874-85. PubMed ID: 23861345
[TBL] [Abstract][Full Text] [Related]
75. Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.
Jain HV; Richardson A; Meyer-Hermann M; Byrne HM
PLoS One; 2014; 9(1):e81582. PubMed ID: 24400068
[TBL] [Abstract][Full Text] [Related]
76. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
[TBL] [Abstract][Full Text] [Related]
77. Human colonic fibroblasts regulate stemness and chemotherapy resistance of colon cancer stem cells.
Colak S; Medema JP
Cell Cycle; 2016 Jun; 15(12):1531-7. PubMed ID: 25483065
[TBL] [Abstract][Full Text] [Related]
78. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.
Xie Z; Bi C; Cheong LL; Liu SC; Huang G; Zhou J; Yu Q; Chen CS; Chng WJ
PLoS One; 2011; 6(6):e21583. PubMed ID: 21720561
[TBL] [Abstract][Full Text] [Related]
79. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
Bolenz C; Becker A; Trojan L; Schaaf A; Cao Y; Weiss C; Alken P; Michel MS
Urol Oncol; 2007; 25(6):476-82. PubMed ID: 18047955
[TBL] [Abstract][Full Text] [Related]
80. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
Zhou H; Aguilar A; Chen J; Bai L; Liu L; Meagher JL; Yang CY; McEachern D; Cong X; Stuckey JA; Wang S
J Med Chem; 2012 Jul; 55(13):6149-61. PubMed ID: 22747598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
